Suspended

Cardiac Screening in Survivors of Hodgkin's Disease Treated With Mediastinal Irradiation

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Echo/Stress Echo

Procedure
Who is being recruted

Hemic and Lymphatic Diseases+6

+ Hodgkin Disease

+ Immune System Diseases

Over 20 Years
See all eligibility criteria
How is the trial designed

Diagnostic Study

Interventional
Study Start: February 2004
See protocol details

Summary

Principal SponsorDana-Farber Cancer Institute
Last updated: January 13, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: February 1, 2004

Actual date on which the first participant was enrolled.

* On the day of the patient's scheduled follow-up visit with their oncologist, additional blood work will be obtained and the patient will fill out questionnaires concerning their general health and assessing quality of life. * A separate cardiology visit with a preventative cardiologist will be performed. At this visit, the patient will undergo a Stress Echocardiogram. * A Stress Echocardiogram is made up of three parts: Resting echo study, stress test and repeat echo while the heart is still beating fast. * A resting echo provides the baseline examination and demonstrates the size and function of various chambers of the heart. * The stress test involves exercise using a treadmill or a stationary bike. In patients who are unable to complete a high level of exercise due to physical limitations, stress to the heart is provided by a pharmaceutical or chemical stimulation to the heart. Exercise is started at a slower, warm-up speed and then increased every 3 minutes. Exercise is abruptly stopped once the patient exceeds 85% of the target rate. EKG recordings are made every minute of exercise and then again after exercise is stopped. Blood pressure is recorded at three minute intervals during exercise and then again at rest. * Immediately after exercise is stopped, the patient will undergo a repeat echocardiogram. * If no cardiac abnormalities are detected, the screening tests will be repeated every 3 years, if the patient is less than 10 years out from their initial treatment. If the patient is more than 10 years from initial treatment, then the tests will be repeated at approximately 18 months from the initial screening and once more at the end of the third year.

Official TitleCardiac Screening in Survivors of Hodgkin's Disease Treated With Mediastinal Irradiation 
Principal SponsorDana-Farber Cancer Institute
Last updated: January 13, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

210 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Diagnostic Study

Diagnostic studies focus on improving how we detect or confirm a disease. They test new tools or techniques that could provide faster or more accurate diagnoses.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 20 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Hemic and Lymphatic DiseasesHodgkin DiseaseImmune System DiseasesImmunoproliferative DisordersLymphatic DiseasesLymphomaLymphoproliferative DisordersNeoplasmsNeoplasms by Histologic Type

Criteria

Inclusion Criteria: * Patients treated at Brigham and Women's Hospital or Dana-Farber Cancer Institute for Hodgkin's disease with mediastinal irradiation * Age \> or = to 15 years of age * Five years or longer after initial treatment * Relapse-free interval of \> 1 year Exclusion criteria: * Patients treated for Hodgkin's disease outside of Brigham and Women's Hospital or Dana-Farber Cancer Institute * Current age \< 15 years of age * Less than 5 years out from initial treatment * Relapses within 1 year

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
Interventions: Participants will * meet with study cardiologist * undergo cardiac risk factors screening * undergo resting and stress echocardiogram (echo and stress echo)

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 2 locations

Suspended

Brigham and Women's Hospital

Boston, United StatesSee the location
Suspended

Dana-Farber Cancer Institute

Boston, United States
Suspended2 Study Centers